Deborah Turner

1.3k total citations · 1 hit paper
13 papers, 554 citations indexed

About

Deborah Turner is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Deborah Turner has authored 13 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 5 papers in Oncology and 3 papers in Genetics. Recurrent topics in Deborah Turner's work include Lymphoma Diagnosis and Treatment (9 papers), Viral-associated cancers and disorders (5 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). Deborah Turner is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Viral-associated cancers and disorders (5 papers) and CNS Lymphoma Diagnosis and Treatment (3 papers). Deborah Turner collaborates with scholars based in United Kingdom, Australia and United States. Deborah Turner's co-authors include Anton Kruger, Andrew McMillan, Eliza A. Hawkes, Paul Mouncey, Christopher Pocock, Joanna Gambell, John Radford, David C. Linch, Kirit M. Ardeshna and Peter Johnson and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Deborah Turner

13 papers receiving 545 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

2013 357 citations David Cunningham, Eliza A. Hawkes et al. The Lancet profile →

Peers

Countries citing papers authored by Deborah Turner

Since Specialization

Citations

This map shows the geographic impact of Deborah Turner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Deborah Turner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Deborah Turner more than expected).

Fields of papers citing papers by Deborah Turner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Deborah Turner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Deborah Turner. The network helps show where Deborah Turner may publish in the future.

Co-authorship network of co-authors of Deborah Turner

This figure shows the co-authorship network connecting the top 25 collaborators of Deborah Turner. A scholar is included among the top collaborators of Deborah Turner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Deborah Turner. Deborah Turner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Real‐world clinical effectiveness and safety of CT‐P10 in patients with diffuse large B‐cell lymphoma: An observational study in Europe 2022 ·SHILAP Revista de lepidopterología ·Mark Bishton, Gilles Salles, Camille Golfier, Wolfgang Knauf, Monica Bocchia, Deborah Turner, Borhane Slama, Jatinder Harchowal, Scott Marshall, Alberto Bosi, (unknown), Manfred Welslau, Sookyoung Kim, (unknown), Pier Luigi Zinzani, Kamel Laribi	2
2	Prognostic indices in diffuse large B‐cell lymphoma in the rituximab era: an analysis of the UK National Cancer Research Institute R‐CHOP 14 versus 21 phase 3 trial 2020 ·British Journal of Haematology ·Mary Gleeson, Nicholas Counsell, David Cunningham, (unknown), Laura Clifton‐Hadley, Eliza A. Hawkes, Andrew McMillan, Kirit M. Ardeshna, Cathy Burton, (unknown), Joanna Gambell, Paul Smith, Paul Mouncey, Christopher Pocock, John Radford, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, David C. Linch	12
3	The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival 2020 ·British Journal of Haematology ·Mark Bishton, Simon Rule, William Wilson, Deborah Turner, Russell Patmore, Laura Clifton‐Hadley, Andrew McMillan, (unknown), Andrew Haynes	5
4	PF314 REAL WORLD CLINICAL EFFECTIVENESS AND SAFETY OF CT-P10 IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: INTERIM RESULTS FROM A EUROPEAN NON-INTERVENTIONAL POST-AUTHORISATION SAFETY STUDY 2019 ·HemaSphere ·Mark Bishton, Deborah Turner, Scott Marshall, Veronica Conteh, Hee Jung Kang, (unknown), (unknown), Pier Luigi Zinzani	1
5	A Comparison of Prognostic Indices in Diffuse Large B-Cell Lymphoma within the UK NCRI R-CHOP 14 Versus 21 Phase III Trial 2018 ·Blood ·Mary Gleeson, Nicholas Counsell, David Cunningham, Eliza A. Hawkes, (unknown), Andrew Jack, Paul Smith, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, David C. Linch	2
6	Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial 2017 ·Annals of Oncology ·Mary Gleeson, Nicholas Counsell, David Cunningham, Nicholas Chadwick, (unknown), Eliza A. Hawkes, Andrew McMillan, Kirit M. Ardeshna, Andrew Jack, Peter Smith, Paul Mouncey, Christopher Pocock, John Radford, J. M. Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch	48
7	Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trial 2016 ·British Journal of Haematology ·Mary Gleeson, Eliza A. Hawkes, David Cunningham, (unknown), Nicholas Counsell, (unknown), Andrew Jack, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch	32
8	R-CHOP in Primary Mediastinal B-Cell Lymphoma (PMBL): Results from the UK NCRI R-CHOP 14 v 21 Trial 2015 ·Blood ·Mary Gleeson, Eliza A. Hawkes, David Cunningham, (unknown), Nicholas Counsell, (unknown), Andrew Jack, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch	3
9	Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma 2014 ·British Journal of Haematology ·Michelle Furtado, Rod Johnson, Anton Kruger, Deborah Turner, Simon Rule	34
10	Risk of CNS Relapse with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era: Results from the UK NCRI R-CHOP 14 v 21 Trial 2014 ·Blood ·Mary Gleeson, David Cunningham, Eliza A. Hawkes, Wendi Qian, Paul Smith, (unknown), Paul Mouncey, Andrew Jack, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch	4
11	Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles breakdown → 2013 ·The Lancet ·David Cunningham, Eliza A. Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M. Ardeshna, John Radford, Andrew McMillan, John Davies, Deborah Turner, Anton Kruger, Peter Johnson, Joanna Gambell, David C. Linch	357
12	Epidemiology and outcomes associated with surgical site infection following bariatric surgery 2012 ·American Journal of Infection Control ·Teena Chopra, Dror Marchaim, (unknown), Chris Kosmidis, Jing Zhao, Sorabh Dhar, (unknown), Deborah Turner, (unknown), Michael Wood, George Alangaden, Keith S. Kaye	28
13	Endometrial carcinoma: Transvaginal ultrasonography prediction of depth of myometrial invasion 1991 ·Gynecologic Oncology ·Vicken Sahakian, Craig H. Syrop, Deborah Turner	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact